EPFL's cancer drug developer Cellestia Biotech has extended its funding haul to $48.6m in a series B round that featured existing investor PPF Group.
Cellestia Biotech, a Switzerland-based small molecule cancer therapy developer spun out of EPFL, completed a CHF20m ($20.4m) series B round yesterday co-led by investment firm FC Capital.
FC Capital co-led the deal with diversified holding company PPF Group, owner of biotech company Sotio, and Partners Investment. The round also featured unnamed new and existing private investors.
Founded in 2014, Cellestia Biotech is working on small molecule cancer drugs that inhibit malfunctioning protein signalling pathways such as Notch, a…
